| EBITDA Margin: guided vs achieved | 24.20% achieved Guided 22.00%–23.00%, 5.2% above the top of the range; confirmed by management |
|---|---|
| EBITDA Margin guidance | 22.5% → 23.0% Raised by 0.5 percentage points |
| Revenue growth | 51% YoY revenue growth reached INR 534 crores. |
|---|---|
| Margins | Structural expansion to 24.2% via tactical specialty focus. |
| Demand visibility | Strong visibility cited for coming quarters, especially in US specialty. |
| Management confidence | Balanced and optimistic regarding specialty pipeline and facility integrations. |
Growth
Strong 51% YoY revenue growth driven by specialty portfolio; EBITDA margins expanded to 24.2% despite geopolitical cost headwinds.
Outlook
EBITDA margin guidance raised to 23% for FY27; Pithampur and US facility commercialization expected by Q4FY27.
Risks
Geopolitical impact on freight/input costs and higher ESOP/pre-revenue costs at new US and Pithampur facilities.
Last quarter's promises, checked
Delivered
- EBITDA Margin 22-23% → delivered 24.2% (= BEAT)
- R&D Productivity ~5.0x → delivered 5.5x (= BEAT)
- Top 5 Concentration ~39% → delivered 36% (= BEAT)
Partly delivered
- Pithampur Inspection Q1CY27 → Site inspected, awaiting final clearance (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: RUBICON. Summary written with AI assistance from the document.
Rubicon Research Ltd: key numbers
- Share price
- ₹1,676.30
- Market cap
- ₹27,748 Cr
- Revenue (annual)
- ₹1,754 Cr
- Net profit (annual)
- ₹246.7 Cr
- P/E (TTM)
- 96.3×Sector 50.4×
- Promoter holding
- 59.76%-0.10% QoQ
- FII holding
- 7.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rubicon Research Ltd
All →Rubicon Research Capital Structure Change
Employee Girish Subramaniam Iyer sold 6,796 shares in the open market across four transactions for a total consideration of ₹1.23 Crore.
- Value
- ₹1.23 Cr
Rubicon Research Other Announcement
Employee Vinayak Sawant sold 1,100 shares of Rubicon Research Ltd worth ₹0.20 Crore. This disclosure is a routine regulatory filing under PIT regulations.
- Value
- ₹0.20 Cr
Rubicon Research Investor Presentation: Key Takeaways
Rubicon Research reported a strong Q1 FY27 with revenue growing 51% YoY to ₹534 Cr and PAT surging over 95% to ₹85 Cr.
Rubicon Research Investor Presentation: Key Takeaways
Rubicon Research reported stellar Q1FY27 results with 51.6% YoY revenue growth. Management revised Operating EBITDA margin guidance upwards to at least 23% for FY27.
Rubicon Research Q1 FY27 Results: Net Profit ₹84.8 Cr, Up 95.8% YoY
Rubicon Research Ltd reported revenue from operations of ₹534.3 Cr (+51.6% YoY) and net profit of ₹84.8 Cr (+95.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹84.8 Cr · +95.8% YoY
Rubicon Research Earnings Call: Key Takeaways
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.